We are extremely proud to announce that the project titled “Longevity Operating System for the Optimisation of Healthy Aging”, presented by RxLongevity, has been financed by the 2023 NEOTEC edition. The development of this project is essential for us, as it will drive the development and improvement of our Rx Longevity technology platform, incorporating artificial intelligence and big data management capabilities to further improve the personalisation of our longevity programmes and optimise the health of our users.

NEOTEC Grant Program

The NEOTEC grant program offers financing to promote the creation, development and consolidation of new technological companies in Spain. A technological company (TC) centers its activity on products or services that require the use of technologies and knowledge that are born from research activities. Therefore, TCs base their business strategy on scientific and technical knowledge and the creation of proprietary R&D avenues.

The goal of the NEOTEC grants, included in the business R&D&i state subprogram, is to promote technology and innovation as competitive factors for the development of businesses. Furthermore, it seeks to increase, extend and systemize both investment and the execution of R&D activities, supporting technological innovation.

Longevity Operating System

Life expectancy in Western countries is around 83 years, while healthy life expectancy is below 64 years. Many older adults experience approximately 20 years of poor health and limiting physical pain, which could be largely preventable, affecting their quality of life and that of their families, as well as the costs of the welfare state.

Ageing is a physiological process with a genetic component of 20% and an epigenetic component (environmental factors and lifestyle) of 80%, which allows each person to influence their ageing process by adopting healthy habits. Rx Longevity's mission is to increase the healthy life expectancy of older adults aged 60 to 80 by 5 years, with the aim of reaching a much wider audience by developing technological products that optimise the ageing process.

Thus, Rx Longevity offers a 'Longevity Plan' that includes biomarker analysis, goal setting and personalised education, exercise and lifestyle recommendations, based on a Longevity Operating System. The app has demonstrated effectiveness in small groups, reducing the risk of falls from 36% to 6% and increasing biomarkers, such as leg strength, related to lower risk of avoidable dependency, in just 2 months of use.

For RxLongevity, this projects means an enormous opportunity to continue our work in the development of cutting-edge technology for early diagnosis of preventable chronic degenerative disease risks at home, developing advanced indicators to assess longevity, and developing personalised programmes to optimise health.